Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...4243444546474849505152...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Immunotherapy Response in Cutaneous Squamous Cell Carcinoma Patients With Cranial Nerve Involvement (JW Marriott Phoenix Desert Ridge Resort and Spa - Grand Canyon 6-8) -  Feb 6, 2022 - Abstract #MHNCS2022MHNCS_223;    
    All patients treated with IO alone demonstrated a clinical response, indicating IO can be an effective monotherapy. Given the challenges of RT with extensive perineural invasion, RT can be reserved in the event of local failure after IO.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Theranostic potential of self-luminescent branched polyethyleneimine-coated superparamagnetic iron oxide nanoparticles. (Pubmed Central) -  Feb 5, 2022   
    SPION@bPEI nanoparticles were further conjugated with Erbitux (Erb), which is an anti-EGFR antibody for targeting EGFR-overexpressing cancer cell lines...Poor GFP expression in MCF7, a slightly better expression in HeLa, and a significant enhancement in the transfection of HCT116 cells proved a selective uptake and hence the targeting ability of Erb-tagged nanoparticles. Altogether, this study proves luminescent, cationic, and small SPION@bPEI nanoparticles as strong candidates for imaging and gene therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Retrospective data, Journal:  Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience. (Pubmed Central) -  Feb 3, 2022   
    For those with RAS and BRAF WT CC, laparoscopic colectomy may favorably impact survival. Definitive RT with or without concurrent systemic agents in patients with unresectable OCC resulted in an eloquent rate of locoregional control and good overall survival rates and is currently the best available treatment option in this patient collective.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Feb 3, 2022   
    P2,  N=74, Active, not recruiting, 
    Definitive RT with or without concurrent systemic agents in patients with unresectable OCC resulted in an eloquent rate of locoregional control and good overall survival rates and is currently the best available treatment option in this patient collective. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. (Pubmed Central) -  Feb 2, 2022   
    The directions include the modification or activation of immune cells and suppression of CAFs and anti-VEGFR agents. In this review, we focus on the mechanisms of resistance to anti-EGFR monoclonal antibodies (anti-EGFR mAbs) and discuss diverse approaches to reverse resistance to this therapy in hopes of identifying more mCRC treatment possibilities.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial primary completion date:  Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer (clinicaltrials.gov) -  Feb 2, 2022   
    P2,  N=30, Recruiting, 
    Trial completion date: Jan 2023 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Jul 2022 Trial primary completion date: Jan 2022 --> Jul 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Long term results of accelerated hypofractionated chemoradiation in oropharyngeal cancer () -  Feb 1, 2022 - Abstract #ECHNOICHNO2022ECHNO_ICHNO_214;    
    Incidence of second malignancy and osteoradionecrosis at 7 years was 11 % (5-22%) and 11% (5-23%) respectively. Conclusion This study provides data on long terms outcomes for 4 week accelerated hypofractionated intensity modulated chemo radiation and suggests that a platinum based 4 week combination might be considered when there is extreme pressure on radiotherapy resource.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Cetuximab as last-line treatment for rmHNSCC outside clinical trials. A retrospective DAHANCA study () -  Feb 1, 2022 - Abstract #ECHNOICHNO2022ECHNO_ICHNO_204;    
    In total 25% of the patients stopped treatment due to deteriorated health or side-effects. Conclusion Cetuximab monotherapy as intended last-line treatment outside clinical trials show efficacy that are in line with data obtained from clinical studies using cetuximab as first-line systemic treatment.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
    Durvalumab with cetuximab and radiotherapy for locally advanced HNSCC: a phase 1/2 trial () -  Feb 1, 2022 - Abstract #ECHNOICHNO2022ECHNO_ICHNO_174;    
    P1/2
    A selective sparing of node levels in the elective volume was performed in all cases, yielding a cumulative mean dose of 37.6 Gy (SD 8.4) (figure 2). Figure 1 Figure 2 Conclusion Albeit limited by the small sample size, our preliminary observation of anti-tumor activity and tolerability of DUR in addition to CTX and radiation may warrant further investigations
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Radical radiation with Tomotherapy in carcinoma Oropharynx, Larynx & Hypopharynx: Indian experience. () -  Feb 1, 2022 - Abstract #ECHNOICHNO2022ECHNO_ICHNO_144;    
    Laryngectomy was done for 8 patients (6 LX, 1 HPX, 1 OPX with supra-glottic extension); 2 for residual disease, 3 for dysfunctional larynx, 3 for recurrence. Conclusion Outcome and toxicity profile in Indian head & neck cancer patients are similar to the published literature.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, sEphB4-HSA / VasGene, National Cancer Institute
    Trial primary completion date, Combination therapy, Metastases:  sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (clinicaltrials.gov) -  Jan 30, 2022   
    P1,  N=3, Active, not recruiting, 
    Conclusion Outcome and toxicity profile in Indian head & neck cancer patients are similar to the published literature. Trial primary completion date: Dec 2021 --> May 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space. (Pubmed Central) -  Jan 29, 2022   
    We analyze these data using a deep learning model, resulting in the identification of a continuous 27-dimension space describing all of the observed cell morphologies. From its morphology alone, we could thus predict whether a cell was resistant to ErbB-family drugs, with an accuracy of 74%, and predict the potential mechanism of resistance, subsequently validating the role of MET and insulin-like growth factor 1 receptor (IGF1R) as drivers of cetuximab resistance in in vitro models of lung and head/neck cancer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal, HEOR, Real-world evidence:  Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany. (Pubmed Central) -  Jan 29, 2022   
    Patients receiving chemoradiation vs chemo-therapy alone showed better overall survival (hazard ratio 0.41, p = 0.014,) and progression-free survival (hazard ratio 0.42, p = 0.009); no differences were observed for metastatic cutaneous squamous cell carcinoma vs locally advanced cutaneous squamous cell carcinoma patients. Although chemotherapy and/or cetuximab showed limited outcomes in advanced cutaneous squamous cell carcinoma, such therapy may still be an option when anti-PD-1 treatment is contraindicated.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    MULTIPLE MECHANISMS OF 5-FLOUROURACIL (5-FU)-ASSOCIATED CHEST PAIN IN A PATIENT WITH METASTATIC SIGMOID CANCER (eAbstract site) -  Jan 28, 2022 - Abstract #ACC2022ACC_5144;    
    We describe a patient who presents with recurrent chest pain on FOLFOX, and multimodality imaging suggestive of independent mechanisms of 5-FU cardiotoxicity.Case: A 43 year-old woman with metastatic sigmoid cancer on FOLFOX and cetuximab presented with positional chest pain 4 days after cycle 7...The patient was treated with colchicine and symptoms resolved... Independent mechanisms of 5-FU-associated chest pain were implicated in our patient through multimodality imaging: pericarditis and microvascular endothelial dysfunction.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Multifunctional niosomes for targeted breast cancer therapy (In-Person Room (Virtual Room)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_13206;    
    These characteristics hold great promise for the development of multifunctional devices that combine several benefits such as biocompatibility, loading capability, and active targeting thus paving the way for the development of more specific and efficient carriers for personalized tumor therapy. Schematic representation of niosomal targeted delivery
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Derivative of benzothiazole (H2) inhibits EGFR tyrosine kinase phosphorylation in oral cancer impacting GLUTs and MCTs (Virtual Room (Marriott Marquis San Diego Marina)) -  Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_10038;    
    Quantitative polymerase chain reaction (qPCR) assays in H2 treated FaDu cells showed marked downregulation of monocarboxylate transporter (MCT) gene expression in vitro. H2 treated 3D spheroid cultures derived from FaDu cells also showed downregulation of glucose transporter 1 (GLUT1) and HK2 gene expression, suggesting regulation of overall cancer cell metabolism.Cancer cell metabolism based small molecule EGFR inhibitor for oral cancer therapy